[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Chiesi Slovenija, d.o.o.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":45},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100630610","fixed-triple-inhaled-combination-in-asthmatic-patients-in-a-real-life-setting-strength-100630610",false,"NCT07489911","Fixed Triple Inhaled Combination in Asthmatic Patients in a Real-life Setting (STRENGTH)","A Prospective Non-Interventional Real-world Study Assessing the Effectiveness of Extrafine BDP\u002FFF\u002FG HS Single Inhaler Triple Therapy (SITT) on Symptom Scores in Asthma Patients After 6 Months Treatment","STRENGTH","INCLUSION CRITERIA:\n\n* Physician-confirmed clinical diagnosis of asthma according to GINA guidelines and treated for at least 3 years before inclusion\n* Patients ≥ 18 years of age in ambulatory care\n* Uncontrolled asthma according to the physician's clinical assessment despite the use of:\n\n  1. LABA and high dose ICS or\n  2. LABA and high-dose ICS + LAMA multi-inhaler triple therapy for a minimum of three months.\n* Patients who are eligible for the use of Trimbow 172\u002F5\u002F9 μg pMDI according to the SmPC :\n\n  1. at least on exacerbation, requiring systemic (oral or intravenous) corticosteroids in the previous 12 months\n  2. uncontrolled asthma (ACT≤15) or partially controlled asthma (15\\\u003CACT\\\u003C20)\n  3. FEV1\\\u003C80% at baseline\n* Inhaled asthma therapy was changed to Trimbow 172\u002F5\u002F9 μg pMDI no more than 1 week prior to OR on the day of study inclusion\n* Patient provided written, informed consent to study participation\n\nEXCLUSION CRITERIA:\n\n* Participation in any clinical trial within 30 days prior to enrolment\n* Patients hospitalized due to an exacerbation of their asthma within the last 4 weeks prior to enrolment\n* Another respiratory condition, apart from asthma or COPD, that may interfere with the effectiveness of the treatment studied AND\u002FOR another important clinical situation that may interfere with patient's compliance with the treatment.\n* Continuous use of oral (\\>5 mg prednisolone\u002Fday OR \\>4 mg methylprednisolone\u002Fday) OR intravenous corticosteroids\n* Use of continuous oxygen therapy\n* Any malignant disease in the last 5 years\n* Tuberculosis (active or anamnestic)\n* Actual or previous use of biologics for asthma treatment in the past 12 months\n* All exclusion criteria listed in Trimbow 172\u002F5\u002F9 μg pMDI SmPC","ALL","18 Years",{"count":20,"type":21},200,"ESTIMATED","OBSERVATIONAL","The mainstay of asthma treatment are ICSs, mostly combined with LABA. In the past decade LAMA had been accepted as an add-on treatment for patients at GINA steps 4 and 5. Recently, RCTs proved the efficacy and safety of fixed triple combinations of moderate and high dose of ICS and LABA, LAMA in a very selected asthmatic population, resulting in the market authorisation of these products. However, there is a lack of evidence on the real-world effectiveness of these therapies, especially with regards to improvement in symptom scores and adherence.",[25,26,27],"Asthma","Asthma Patients","Asthma Bronchiale",[29,25,30,31],"Single Inhaler Triple Therapy","SITT","Trimbow","RECRUITING","2026-03-18",{"date":35,"type":36},"2026-03-24","ACTUAL",{"date":38,"type":36},"2024-11-04",{"date":40,"type":21},"2026-07",{"name":42,"class":43},"Chiesi Slovenija, d.o.o.","INDUSTRY",18,""]